Capstan Medical, a startup focused on robotic-assisted mitral and tricuspid valve replacement, recently completed its first ...
Capstan CEO Maggie Nixon discusses first-in-human feedback, the all-at-once approach, regulatory strategy and the tricuspid ...
An Infirmary Health doctor has been the first person to perform a TriClip G4 procedure in Mobile successfully and one of the ...
In the midst of transformative transcatheter approaches to repair diseased aortic and mitral valves, the tricuspid valve has been overshadowed, according to Michael E. Bowdish, MD, vice chair of ...
"Today marks a pivotal moment in the evolution of structural heart therapy," Capstan Medical CEO Maggie Nixon said.
Capstan Medical announced its first in-human cardiac valve replacements using its catheter-based robotic surgical platform.
In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to ...
Why it matters: Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue from new transcatheter mitral and tricuspid ...
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $105 million for the quarter, supported by the strong adoption of the PASCAL repair system and EVOQUE replacement system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback